Results 41 to 50 of about 444,347 (295)
ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
Кардиоваскулярная терапия и профилактика, 2013 The paper presents the results of experimental studies and clinical trials which demonstrate nephroprotective effects of olmesartan.
V. V. Fomin
doaj +1 more source
Advanced Science, EarlyView.We identify an antagonistic ubiquitin circuit that controls cellular permissiveness to multiple coronaviruses. The deubiquitinase USP7 stabilizes the epigenetic regulator KDM6A to upregulate viral receptors, while the E3 ligase RNF40 degrades KDM6A by catalyzing K6/K11‐ubiquitin chains of KDM6A for autophagic degradation.
Meng‐Zhuo Huang +9 more
wiley +1 more source
ANGIOTENSIN II RECEPTOR ANTAGONISTS AND PROTEINURIA
Zdravniški Vestnik, 2002 Background. In numerous clinical studies that tried to identify risk factors for progressive renal function loss, the severity of proteinuria correlated with the rate of renal function loss.
Tanja Kök, Radovan Hojs
doaj
Advanced Science, EarlyView.We generated multi‐tissue single‐cell transcriptomic atlases of camels and cattle, uncovering conserved and lineage‐specific cellular features across digestive and metabolic systems. Cross‐species comparisons revealed the evolutionary origin of the camel glandular sac and identified novel cell populations linked to physiological specialization ...
Tao Shi +22 more
wiley +1 more source
Suppression of Aldosterone Synthesis and Secretion by Channel Antagonists
International Journal of Endocrinology, 2012 Aldosterone, a specific mineralocorticoid receptor (MR) agonist and a key player in the development of hypertension, is synthesized as a final product of renin-angiotensin-aldosterone system.
Keiichi Ikeda +4 more
doaj +1 more source
Comparison of angiotensin II receptor antagonists [PDF]
European Journal of Clinical Investigation, 2001 Nonpeptide orally active angiotensin II type 1 (AT1) receptor antagonists are the most specific means presently available to block the renin‐angiotensin enzymatic cascade. Six of these drugs have already been licensed in Europe and in the United States for the treatment of high blood pressure, and additional candidates are in the pipeline.
W, Kirch, B, Horn, J, Schweizer
openaire +2 more sources
Advanced Science, EarlyView.ABSTRACT Intestinal ischemia/reperfusion (I/R) injury presents a biphasic pathology: an acute oxidative‐inflammatory phase leading to organ failure, and a recovery phase marked by mucosal dysfunction and bacterial translocation. The developed MPB@TA‐Cu‐Ma nanocomposite functions as a dual‐phase therapeutic platform with significant efficacy. It rapidly
Chenghao Qiu +15 more
wiley +1 more source
Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond
Advanced Science, EarlyView.Therapeutic gases, including NO, CO, H2S, H2, CO2, O2, and Xe, play vital roles in cellular signaling and repair. This review highlights the emerging carriers and delivery systems that enable controlled, localized gas release for diagnostic and therapeutic applications.
Syed Muntazir Andrabi +4 more
wiley +1 more source
G protein coupled receptors of the renin-angiotensin system: new targets against breast cancer?
Frontiers in Pharmacology, 2015 G-protein coupled receptors (GPCRs) constitute the largest family of membrane receptors, with high potential for drug discovery. These receptors can be activated by a panel of different ligands including ions, hormones, small molecules and vasoactive ...
Clara eNAHMIAS +1 more
doaj +1 more source
ESC Heart Failure, 2020 Aims In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the publication ...
Fernando deFrutos +15 more
doaj +1 more source